Are there differences among bacillus Calmette-Guérin (BCG) strains regarding their clinical efficacy in the treatment of non-muscle-invasive bladder cancer? The jury is still out but the answer is likely no

Auteurs-es

  • Guan Hee Tan Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, ON, Canada.
  • Cynthia Kuk Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, ON, Canada
  • Alexandre R. Zlotta Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, ON, Canada

DOI :

https://doi.org/10.5489/cuaj.5923

Mots-clés :

bladder cancer, BCG, Bacillus Calmette-Guérin, non-muscle invasive bladder cancer, NMIBC, immunotherapy

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Publié-e

2019-07-23

Comment citer

Tan, G. H., Kuk, C., & Zlotta, A. R. (2019). Are there differences among bacillus Calmette-Guérin (BCG) strains regarding their clinical efficacy in the treatment of non-muscle-invasive bladder cancer? The jury is still out but the answer is likely no. Canadian Urological Association Journal, 14(2), E54–6. https://doi.org/10.5489/cuaj.5923

Numéro

Rubrique

Research Letter